Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Synthetic Conjugated estrogens, B · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Synthetic Conjugated estrogens, B | DRUG | 1 (0.3mg) tablet daily |
| Placebo | OTHER | 1 tablet daily |
Inclusion Criteria: * Naturally or surgically postmenopausal * Moderate or severe symptoms of vaginal atrophy (ie, dryness, itching, pain, uncomfortable intercourse) Exclusion Criteria: * Known sensitivity or contraindication to estrogens or progestins * History or current diagnosis of endometria...
Synthetic Conjugated estrogens, B is a small molecule estrogen therapy developed by Teva Pharmaceutical Industries Limited for the treatment of menopause. It is an investigational product in Phase 3 clinical development. It is designed as an agonist of the estrogen receptors ESR1 and ESR2.
Synthetic Conjugated estrogens, B is being developed for the treatment of menopause. The Phase 3 clinical trial evaluated it for vulvovaginal atrophy, a common condition associated with menopause. It is not yet approved and remains under clinical investigation.
Synthetic Conjugated estrogens, B targets the estrogen receptors ESR1 and ESR2. It acts as an agonist at these receptors, meaning it activates them to produce estrogen-like effects. This mechanism underlies its development for menopause-related conditions.
Synthetic Conjugated estrogens, B is developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. Teva is the sponsor responsible for the clinical development of this asset.
Synthetic Conjugated estrogens, B is in Phase 3 clinical development. The single Phase 3 trial has been completed, and no active trials are currently listed. It is an investigational therapy and has not been approved for any indication.
Synthetic Conjugated estrogens, B has been studied in one Phase 3 clinical trial, NCT00196378, titled A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy. The trial was completed, enrolled 300 participants, and was randomized, double-blind, and placebo-controlled.